Objective: To determine whether there is an association between an acute preceding hepatitis E virus (HEV) infection and neuralgic amyotrophy (NA), and if so, whether patients with HEV-related NA differ from patients without an associated HEV infection.
conduction study and EMG reports (January 2011 to April 2013). Twenty-six additional cases of NA were identified, and of these patients, sera for HEV testing were available in 7.
Dutch patients. All patients attended the Department of Neurology of the Radboud University Nijmegen Medical Centre between October 2004 and June 2007 to take part in a prednisone treatment trial for NA. Patients were seen in the acute phase (within 4 weeks from onset of neurologic symptoms) with a welldocumented attack of acute, severe shoulder and/or arm pain followed by paresis, in whom diagnoses other than NA were excluded. For the NA diagnoses, we used the criteria of Hannibal et al. for hereditary NA, although we did not consider family history. 21 Nerve conduction and EMG studies supported the clinical diagnosis, and an MRI of the cervical spine was performed to exclude degenerative pathology as a cause of symptoms when necessary. None of the patients had a history of autoimmune disease or Guillain-Barré syndrome (GBS), or had been treated with immune-modulating medication at the time of presentation to the outpatient clinic. In addition to historytaking, a standard (pretreatment) questionnaire was completed by the patients to assess recent antecedent events and patients were clinically evaluated in a standardized manner at 3 and 6 months. Serum samples were obtained at first presentation (within 4 weeks of onset of pain and neurologic symptoms) and 2 weeks later. Sera were stored aliquoted at 280°C until use.
Standard protocol approvals, registrations, and patient consents. Ethical committee approval for the work in the United Kingdom was not appropriate, because it was considered by the clinicians and virologists involved as an investigation of a possible outbreak. However, the patients whose clinical details are described gave informed consent. The local ethics committee (CMO Nijmegen/Arnhem) approved the Dutch study, and patients were included in this study after providing written informed consent.
Virologic testing. All available serum samples were tested for the presence of anti-HEV immunoglobulin (Ig) M and IgG using commercially available HEV ELISAs (Wantai, Beijing, PR China), according to the manufacturer's instructions. Samples with a signal-to-noise ratio ,1.1 were considered negative. All anti-HEV IgM-positive samples were screened for the presence of HEV RNA (figure 1), using a previously described, internally controlled, quantitative real-time reverse transcription PCR. 22, 23 The reverse transcription PCR had a lower limit of detection (95% hit rate) of 143 (2.16 log) IU/mL as determined by the first World Health Organization standard for HEV RNA nucleic acid amplification techniquebased assays (code 6329/10, Paul Ehrlich Institute, Langen, Germany). 24 Phylogenetic analysis of HEV-ORF1b was performed as described previously to determine genotype and to exclude a common source of infection. 22, 23 The sequences of all isolates were deposited into GenBank under accession number KF219921.
Case definition. A case of hepatitis E was defined as:
• HEV PCR-positive and/or • IgM-and IgG-positive or • IgM-positive, IgG-negative at presentation, but IgGpositive on a second serum sample.
Statistical analysis. Differences in proportions were tested
using the x 2 test, Fisher exact test, or the Kruskal-Wallis test, and differences in continuous variables were tested using the Mann-Whitney U test. A p value ,0.05 was considered to be statistically significant. Statistical analysis was performed using SPSS version 20 (IBM Corp., Armonk, NY).
RESULTS
Five cases (10.6%) of hepatitis E infection were identified from a total of 47 patients with NA who were tested for HEV. Anti-HEV IgM was detected in 2 of 9 Cornish and 3 of the 38 Dutch patients with NA (table, figure 1 ). All 5 patients were anti-HEV IgG-positive, or became positive in the follow-up sample after 2 weeks. HEV RNA was detected in serum in all 4 patients who were tested early (days 1, 4, 7, and 15) after the onset of NA symptoms. Further characterization classified one strain within genotype 3 (case 3, figure e-1 on the Neurology ® Web site at www.neurology.org); the viral loads of the other HEV RNA-positive samples were too low for Sanger sequencing. One patient (case 2) presented 3 months after symptom onset; anti-HEV IgG and IgM serology was positive (table), but no HEV RNA could be detected in his serum at this stage.
Of the 47 patients with NA tested in total, 13 had anti-HEV IgG (figure 1). In patients without confirmed recent hepatitis E infection (n 5 42), anti-HEV IgG was found in 8. This included 7 of the Dutch cohort, so in total 10 (26%) of 38 Dutch patients with NA had anti-HEV IgG. One patient from the Dutch cohort had a modestly elevated anti-HEV IgM signal-to-noise ratio (2.28) with negative PCR and negative anti-HEV IgG. The anti-HEV IgM result was therefore considered to be false-positive.
Twenty-eight patients with NA were identified in the Cornish cohort, but only 5 of these patients had their liver function tests checked within 1 month of symptom onset. Two of these patients (including case 1) had mildly abnormal liver function with an alanine aminotransferase of 66 and 313 IU/L, respectively, and a normal bilirubin. In the Dutch cohort, 9 of 38 patients (24%) had mildly abnormal liver function (alanine aminotransferase median 98 U/L, range 48-396; bilirubin 27 mmol/L in 1 patient), including cases 3 and 5 (table, figure 1 ).
The patients with HEV-associated NA were aged between 34 and 40 years, compared with a median age of 40 years (range 23-72) in the patients without hepatitis E infection; 4 were male and 1 female (table). Before onset of neurologic symptoms, one patient developed symptoms of an upper respiratory tract infection, and another patient had diarrhea. None of the patients reported traveling to areas traditionally considered hyperendemic for HEV in the 3 months before symptom onset. All had clinical evidence of patchy bilateral involvement of the brachial plexus. EMG confirmed bilateral patchy axonal involvement predominantly of the upper trunk of the brachial plexus in all patients (figure e-2). In 4 of the patients with HEV-associated NA, the neurologic injury was worse in the dominant arm. All patients showed some symptomatic improvement, but all had significant residual neurologic impairment at 6 months (table) .
All of the patients with HEV-associated NA had bilateral brachial plexus involvement, compared with 15 of 35 (43%) of the Dutch cohort without recent evidence of hepatitis E infection. In the Dutch cohort, the presence of anti-HEV IgM was not related to age, sex, disease severity (functional disability scale), presence of sensory deficits, prednisone use, and outcome at 6 months (functional disability scale), or any specific preceding symptoms of an infection. Both groups showed a slow recovery over 6 months, with significant residual deficits. DISCUSSION The current study suggests that approximately 10% of patients with NA have acute hepatitis E infection at the start of their neurologic illness. The patients with HEV-associated NA were aged between 34 and 40 years and had modestly elevated serum transaminases with bilateral brachial plexus involvement and residual functional impairment at 6-month follow-up. The evidence suggests that hepatitis E infections documented in the patients with NA were locally acquired, because none had traveled to an HEV-endemic area and HEV genotype 3 was found in the single patient in whom viral sequencing was possible. HEV genotype 3 is the dominant genotype in Europe in both human and pig populations. 10, 11, 22 It is not possible to be certain what proportion of patients with NA have an associated hepatitis E infection, because some of the Cornish patients were studied in retrospect. This may have led to case ascertainment bias. However, the Dutch cohort, although small, was prospectively studied and rigorously defined. Analysis of the data from our Dutch cohort suggests that 8% of patients with NA have an associated infection with HEV. Our data should be interpreted in light of a recent large Dutch study: 49 of 5,239 (0.9%) healthy blood donors tested positive for anti-HEV IgM and 4 (0.0008%) were HEV RNA-positive. 25 Although previous studies show a large proportion of patients with NA report clinical symptoms of a preceding infection, extensive serologic studies on the type of infections in NA have not been conducted. 18 Many case reports of NA related to a range of microorganisms have been published. So far, case series have been published in relation to a recent infection with Bartonella and coxsackie virus type A2, but controlled studies in larger groups are required to define whether or not they are associated with NA. 7, 26 The abnormalities in liver function are transient and mild, and none of the patients with NA were clinically jaundiced. The Cornish data demonstrate that in standard clinical practice, liver function tests are rarely checked in patients with NA. These observations mean that there are often either no (or very subtle) clinical or biochemical prompts for the physician to consider viral hepatitis as a diagnostic possibility. Patients with NA often present late, because they are initially thought to have musculoskeletal problems (as illustrated by case 2) and may take a rather circuitous route to a neurologist. 18 "Late presenters" are usually HEV PCR-negative when tested, because viremia in hepatitis E infections is often brief in immunocompetent patients. 10, 11 The mechanism by which HEV triggers NA is uncertain. Direct infection of the brachial plexus cannot be excluded because HEV RNA was demonstrated in all HEV-associated patients at the start of their illness. Alternatively, HEV may trigger an immune response that damages the peripheral nervous system, similar to the pathogenesis of GBS. Both are monophasic disorders and more frequent in men, in contrast to many classic autoimmune diseases. In the current 2 studies, we identified a new link between these 2 disorders that both may be preceded by a recent hepatitis E infection. Interestingly, the frequency of HEV infections preceding NA and GBS are similar: 8%-10% and 5%, respectively. The cases of HEV-associated NA we have documented all had bilateral peripheral nervous system involvement as seen in GBS. The phenotype of (asymmetric) bilateral NA is generally seen in 25% to 30% of the patients with NA. 18 In all previous case reports of HEVassociated NA, there was bilateral involvement of the brachial plexus. 9, [12] [13] [14] [15] [16] [17] Given the similarities between GBS and NA, these disorders may represent 2 clinical syndromes in the same spectrum of immune-mediated peripheral nerve disorders, related to HEV infection.
At present, there is no evidence that HEV-related NA should be treated differently than any other forms of NA. Further studies are required to confirm our findings and to demonstrate whether patients are viremic at presentation. If this proves to be the case, one could consider treatment with antiviral therapy, but at present this is speculative.
The results of our study suggest that an acute hepatitis E infection is found in approximately 10% of patients with NA from the United Kingdom and the Netherlands. The pathophysiologic relationship remains to be established, as does the role of HEV in patients with NA in other geographical settings. The finding that hepatitis E is associated with both NA and GBS adds weight to the notion that these syndromes reflect differing parts of the same spectrum of neurologic immune-mediated diseases.
